Raymond James Trust’s GSK GSK Stock Holding History

Raymond James Trust’s Portfolio GSK Stock Details GSK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	$1.88M	Buy	45,948 +2,969	+7%	+$121K	0.04%	336
2024 Q2	$1.65M	Sell	42,979 -323	-0.7%	-$13.6K	0.04%	350
2024 Q1	$1.86M	Sell	43,302 -700	-2%	-$28.9K	0.05%	326
2023 Q4	$1.63M	Sell	44,002 -3,865	-8%	-$139K	0.04%	342
2023 Q3	$1.74M	Sell	47,867 -929	-2%	-$33K	0.05%	303
2023 Q2	$1.74M	Buy	48,796 +2,145	+5%	+$76.9K	0.05%	305
2023 Q1	$1.66M	Buy	46,651 +5,395	+13%	+$189K	0.05%	292
2022 Q4	$1.45M	Buy	41,256 +56	+0.1%	+$1.86K	0.05%	311
2022 Q3	$1.21M	Sell	41,200 -1,381	-3%	-$52.3K	0.05%	329
2022 Q2	$2.32M	Buy	42,581 +944	+2%	+$52.1K	0.08%	221
2022 Q1	$2.27M	Buy	41,637 +1,334	+3%	+$72.5K	0.07%	248
2021 Q4	$2.22M	Sell	40,303 -492	-1%	-$25.6K	0.07%	250
2021 Q3	$1.95M	Buy	40,795 +1,497	+4%	+$75.2K	0.07%	260
2021 Q2	$1.96M	Sell	39,298 -1,330	-3%	-$63.9K	0.07%	257
2021 Q1	$1.81M	Sell	40,628 -5,683	-12%	-$258K	0.06%	254
2020 Q4	$2.13M	Sell	46,311 -14,235	-24%	-$654K	0.08%	215
2020 Q3	$2.85M	Sell	60,546 -2,009	-3%	-$101K	0.12%	150
2020 Q2	$3.19M	Sell	62,555 -4,753	-7%	-$244K	0.15%	133
2020 Q1	$3.19M	Buy	67,308 +142	+0.2%	+$7.58K	0.19%	119
2019 Q4	$3.94M	Buy	67,166 +104	+0.2%	+$5.79K	0.19%	116
2019 Q3	$3.58M	Buy	67,062 +1,804	+3%	+$92.8K	0.18%	117
2019 Q2	$3.27M	Sell	65,258 -2,464	-4%	-$124K	0.18%	124
2019 Q1	$3.54M	Sell	67,722 -24	-0%	-$1.2K	0.2%	113
2018 Q4	$3.23M	Sell	67,746 -6,160	-8%	-$303K	0.21%	111
2018 Q3	$3.71M	Sell	73,906 -3,173	-4%	-$161K	0.21%	107
2018 Q2	$3.88M	Sell	77,079 -199	-0.3%	-$10K	0.24%	100
2018 Q1	$3.77M	Buy	77,278 +2,767	+4%	+$129K	0.26%	95
2017 Q4	$3.3M	Buy	74,511 +1,048	+1%	+$48.4K	0.22%	104
2017 Q3	$3.73M	Buy	73,463 +5,658	+8%	+$287K	0.27%	96
2017 Q2	$3.65M	Sell	67,805 -38,008	-36%	-$2.03M	0.27%	96
2017 Q1	$5.58M	Buy	105,813 +3,521	+3%	+$179K	0.42%	60
2016 Q4	$4.92M	Sell	102,292 -7,539	-7%	-$372K	0.39%	64
2016 Q3	$5.92M	Sell	109,831 -1,053	-0.9%	-$57.7K	0.51%	50
2016 Q2	$6.01M	Buy	110,884 +3,559	+3%	+$187K	0.53%	46
2016 Q1	$5.44M	Buy	107,325 +49,597	+86%	+$2.47M	0.51%	49
2015 Q4	$2.91M	Buy	57,728 +3,894	+7%	+$198K	0.27%	89
2015 Q3	$2.59M	Sell	53,834 -4,750	-8%	-$247K	0.29%	85
2015 Q2	$3.05M	Buy	58,584 +3,065	+6%	+$173K	0.32%	80
2015 Q1	$3.2M	Buy	55,519 +3,668	+7%	+$210K	0.34%	78
2014 Q4	$2.77M	Sell	51,851 -2,191	-4%	-$123K	0.3%	85
2014 Q3	$3.11M	Buy	54,042 +7,042	+15%	+$432K	0.36%	75
2014 Q2	$3.14M	Buy	47,000 +6,790	+17%	+$460K	0.36%	76
2014 Q1	$2.69M	Sell	40,210 -16,094	-29%	-$1.09M	0.33%	82
2013 Q4	$3.76M	Buy	56,304 +767	+1%	+$49.7K	0.49%	54
2013 Q3	$3.48M	Buy	55,537 +2,667	+5%	+$172K	0.54%	42
2013 Q2	$3.3M	Buy	+52,870	New	+$3.36M	0.54%	41

Other funds holding GSK

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

JEST

JTC Employer Solutions Trustee St Helier, Jersey $1.2B AUM 37.55% 1-Year Est. Return

Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Raymond James Trust's GSK Position: Q3 2024 in Review

Raymond James Trust increased its GSK (GSK) stake by 6.9% in Q3 2024, buying an estimated $121K and bringing the position to 45,948 shares worth $1.88M. The position accounts for 0.04% of the portfolio, ranked #336.

Raymond James Trust first reported a position in GSK in Q2 2013 and has held it in 46 quarters since. The position peaked at $6.01M in Q2 2016. 899 funds tracked by Wall St. Rank hold GSK as of Q3 2024.

Raymond James Trust held 45,948 shares of GSK worth $1.88M as of Q3 2024.
Raymond James Trust bought 2,969 GSK shares in Q3 2024, an estimated $121K.
GSK made up 0.04% of Raymond James Trust's portfolio in Q3 2024, its #336 holding.
Raymond James Trust first reported a position in GSK in Q2 2013 and has held it in 46 quarters since.
Raymond James Trust's GSK position peaked at $6.01M in Q2 2016.
899 funds tracked by Wall St. Rank held GSK as of Q3 2024.

Based on Raymond James Trust's 13F filing for Q3 2024, filed 12 Nov 2024.